<a href="https://www.fiercebiotech.com/biotech/asco-tubulis-touts-ovarian-cancer-data-attracted-gilead-buyout-deal-closes" hreflang="en">ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’</a>
Gilead Sciences highlighted promising data from Tubulis' antibody-drug conjugate TUB-040, which showed a 61% tumor shrinkage rate in patients with platinum-resistant ovarian cancer, supporting Gilead's $3.15 billion acquisition of Tubulis. The results, presented at the ASCO 2026 meeting, indicate TUB-040's potential to outperform existing treatments and set the stage for further clinical development.
The most valuable insight for you is Gilead's strategic acquisition of Tubulis, which underscores the potential of antibody-drug conjugates (ADCs) in treating platinum-resistant ovarian cancer, as evidenced by the impressive phase 1 data of TUB-040. This acquisition not only strengthens Gilead's oncology portfolio but also highlights the importance of innovative platforms that allow flexibility in ADC development, potentially expanding applications beyond cancer into inflammation and virology. Keep an eye on Gilead's ADC innovation center in Munich as a hub for advancing these technologies.